Skip to content

XOMA Corporation XOMA Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Zymeworks logo
ZymeworksZYME
ALN
Alnylam PharmaceuticalsALNY
Xencor logo
XencorXNCR
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's proceeds from exercises of stock options and other stock issuances?
XOMA Corporation (XOMA) reported proceeds from exercises of stock options and other stock issuances of $565K in Q1 2026.
How has XOMA Corporation's proceeds from exercises of stock options and other stock issuances changed year-over-year?
XOMA Corporation's proceeds from exercises of stock options and other stock issuances increased by 73.8% year-over-year, from $325K to $565K.
What is the long-term trend for XOMA Corporation's proceeds from exercises of stock options and other stock issuances?
Over 3 years (2021 to 2025), XOMA Corporation's proceeds from exercises of stock options and other stock issuances has grown at a 47.1% compound annual growth rate (CAGR), from $1.58M to $5.05M.